AL2846

AL2846 is a small-molecule drug developed by Chia Tai Tianqing Pharmaceutical. Its targets are MET, RET and KIT (the sponsor names c-MET, c-KIT, VEGFR1, RET). The sponsor states: A multi-target tyrosine kinase inhibitor capsule with significant inhibitory effects on c-MET, c-KIT, VEGFR1 and RET. ClinicalTrials.gov describes the intervention as: AL2846 Capsule is a multi - target tyrosine kinase inhibitor, which has significant inhibitory effects on c-Mesenchymal-epithelial transition factor (c - MET), stem cell factor receptor (c - KIT), VEGFR1 and Ret Proto-Oncogene (RET). It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT06860971 (A Study of AL2846 Capsule Versus Placebo in the Treatment of Advanced Radioiodine-Refractory Differentiated Thyroid Carcinoma), in thyroid cancer. The largest, NCT06860971, plans to enrol 144 participants with primary completion expected 2027-01. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.